Best Practices for Evaluation and Treatment of Agitated Children and Adolescents (BETA) in the Emergency Department

Consensus Statement of the American Association for Emergency Psychiatry

Ruth Gerson, MD; Nasuh Malas, MD, MPH; Vera Feuer, MD; Gabrielle H. Silver, MD; Raghuram Prasad, MD; Megan M. Mroczkowski, MD; Pediatric BETA Consensus Guideline Working Group

Disclosures

Western J Emerg Med. 2019;20(2):409-418. 

In This Article

Results

The following summarizes the consensus recommendations for the evaluation and pharmacological management of agitation among pediatric patients in the ED.

Multimodal Approach

There is consensus that management of agitation in the ED should be individualized, multidisciplinary, and collaborative. Medication should serve as one part of a comprehensive strategy to address the behavior. Clinicians should attempt to understand the etiologic factors leading to agitation, use non-pharmacologic de-escalation strategies, and choose medication based on the patient's specific needs and history. For example, consider a child with autism who is brought to the ED for aggression triggered by anxiety, who then becomes agitated and attempts to flee the ED due to hunger and sensitivity to fluorescent lights. Effective treatment requires addressing his anxiety (considering non-pharmacologic and pharmacologic interventions), hunger, and sensory needs. In many cases, addressing etiologic factors proactively and non-pharmacologically can obviate or completely eliminate the need for pharmacologic management.

Etiology Drives Choice of Treatment

There is consensus that, whenever possible, the etiology of agitation should be ascertained and all treatments targeted to the root causes of the agitation. Diagnostic assessment occurs in parallel with symptomatic management. Collateral information, response to non-pharmacologic interventions, mental status and change in symptoms over time inform this ongoing assessment. While standardized scales are often used in adult settings, there are few broadly used, evidence-based tools for pediatric agitation; thus, thoughtful clinical assessment is imperative. Cross-disciplinary collaboration and communication is also key to identifying potential causes of agitation. The bedside nurse is uniquely suited to notice changes in the patient's mental status or behavior, implement non-pharmacologic strategies early, and quickly engage crisis services. Family members provide a crucial premorbid developmental and behavioral baseline of their child and may help elucidate the cause of agitation.

The assessment of etiology starts with asking why the child has become agitated now and here, considering antecedents such as environmental or interpersonal triggers, as well as internal stressors such as pain or acute psychiatric symptoms. Psychiatric history, medication review, including any potential for toxic ingestion (intentional or accidental), allergies, past medical history, developmental history and a focused social and family history, including trauma history, should also be obtained.[21]

Medical evaluation of agitated patients is critical, although completing a full physical examination and any indicated laboratory/imaging studies may be challenging during acute agitation. If the etiology of agitation is unknown or mixed, there is consensus that the clinician should use best clinical judgment and provide symptomatic management based on available diagnostic and clinical information. The clinician should continuously reevaluate the differential diagnosis, observing response to intervention closely, and adjust diagnostic assessment and management accordingly.

Differential Diagnosis

Agitation is a symptom, like pain, with many potential etiologies and often multiple factors contributing in the moment. The potential etiologies for acute agitation among youth in the ED includes physical disease (such as pain, delirium, intoxication and catatonia), anxiety, developmental and cognitive disabilities, behavioral disorders, trauma, mania, psychosis, sensory or physical limitations, and difficulty communicating needs. Even if a child has a known history of psychiatric or developmental disorders, comorbid physical disease, anxiety or other acute triggers should still be ruled out and a broad differential maintained. Non-pharmacologic approaches used for de-escalation should be employed early with a preventative, proactive approach.

Non-pharmacologic Management

There is consensus that non-pharmacologic approaches should be used to prevent and de-escalate agitation before pharmacologic measures are considered. A multidisciplinary approach allows primary and secondary prevention strategies. Primary prevention includes changes to the ED environment to make youth more comfortable, clear communication to reduce anxiety, and effective assessment and treatment of pain and other acute physical symptoms. Secondary prevention includes modifications for youth identified to be at baseline elevated risk for agitation or for youth beginning to show signs of agitation. Family members may identify calming strategies that have been effective in the past, which may contribute to crisis and behavioral planning. An agitated child should be moved away from other patients to a calming, safe area without access to sharps and dangerous objects.[21]

Even if a youth in the ED is becoming highly agitated, simple non-pharmacologic de-escalation strategies can be effective and should always be attempted before, with, and after pharmacotherapy. Communicating in a neutral yet empathic tone, communicating at the patient's eye level, and using clear, concrete and simple language (or visual communication tools for youth with developmental disabilities) are helpful. Reunification with (or separation from) family members, food, drink, distraction, preferred comfort items from home, or sensory coping kits can ease tension. Firm limits on unacceptable behaviors and specific praise for adherence to requests and de-escalation mold behavior while also modeling for families how to parent in the face of disruptive behaviors. Reflective statements and validation help youth who struggle with articulating complex emotions feel understood, while clarifying triggers for agitation and promoting problem-solving.

Rationale for Medication use

The goal of pharmacotherapy is twofold: 1) target the underlying cause of distress; and 2) calm the patient sufficiently for rapid assessment and treatment.

While medication for agitation is often considered when non-pharmacologic interventions have "failed," pharmacologic and non-pharmacologic strategies should be used in concert with non-pharmacologic de-escalation efforts continuing during and after medication administration. When medication is used, it should be calming but not excessively sedating, as a youth who is asleep cannot be evaluated, participate in care, or leave the ED. Medication should be chosen for its calming effect but also to address the underlying etiology of the youth's distress, so no one medication will be appropriate for all patients or all types of agitation.

General Recommendations Regarding Medication Use (Table 1, Table 2)

A current medication list and medication history (including prior STAT/PRN medication use) helps to avoid drug interactions and adverse drug events (ADEs) and inform medication choice and dosing. Often a half dose or extra dose of a home medication can ameliorate escalating agitation. There is neither firm evidence nor consensus to support the use of one medication or even class of medication for all patients. Risks of ADEs should be weighed against potential benefit, while considering patient age, weight, medical comorbidity, and development when choosing a medication. There is consensus that PO administration should be tried whenever possible before the IM route. If intravenous access is already in place and safely accessible, this is preferred to IM administration. Neuroleptics should be used judiciously, only when truly indicated, and with appropriate monitoring, given potential adverse effects, particularly extrapyramidal adverse effects. Response to any intervention should be observed and documented closely. (Table 1 and Table 2)

Diphenhydramine, benzodiazepines, and alpha-2 agonists are generally calming and can also provide symptom-focused treatment. Diphenhydramine, with a more benign ADE profile and greater familiarity among families and medical providers, should be considered for younger children, youth with mild to moderate anxiety, youth with severe anxiety not secondary to delirium, intoxication, or withdrawal, and youth with mild agitation and no clear psychiatric or significant physical health history. Diphenhydramine and benzodiazepines should be avoided in delirium or in children where there is history of, or concern for, paradoxical disinhibition. Alpha-2 agonists can also provide symptomatic management of anxiety, hyperactivity, and hyperarousal, although these medications require blood pressure monitoring.[22]

Neuroleptics can be considered for most causes of severe agitation. Total daily dose should be monitored closely. Olanzapine can potentially be more sedating than haloperidol or risperidone and has less risk for cardiac adverse events or extrapyramidal symptoms. Given the risk of respiratory suppression if given concomitantly with benzodiazepines, olanzapine and benzodiazepines should not be administered parenterally within one hour of each other.[23] Despite the studies noted above of PRN ziprasidone for agitation in psychiatric inpatients, there is consensus that ziprasidone is not recommended due to its activating potential, QT prolongation risk, and need for concomitant food intake when administered PO.

There is consensus that if an initial dose of medication was ineffective, a second dose of the same medication is preferable to adding multiple different medications (unless limited by ADE), as children can be vulnerable to drug-interaction adverse effects. An exception to this was combining haloperidol and lorazepam, which was generally considered preferable to a second dose of a neuroleptic in non-delirious patients. The etiology of agitation should be reassessed continuously, especially after two doses of a particular medication, and youth who have received multiple doses should be monitored continuously. Total daily dose or not to exceed instructions should be written and cumulative doses monitored, lest akathisia, delirium, and iatrogenic syndromes such as neuroleptic malignant syndrome be misperceived as worsening agitation.

There is consensus that ketamine and barbiturates are not recommended for treatment of agitation and that opioid analgesics should not be used for agitation unless for pain control.

Specific Guidelines for Medication use (Figure)

Below are the consensus medication regimens for the five most common etiologies of agitation: delirium; substance intoxication/withdrawal; developmental disability-related; psychiatric diagnosis; and unknown ctiology. Youth may present with agitation of mixed etiology, for example an adolescent with bipolar disorder who presents intoxicated, or a child with autism spectrum disorder who is delirious secondary to medical illness. In such complex cases, the ED clinician should use his or her best judgment in assessing the relative contribution of each etiologic factor to the presentation and strongly consider consulting child and adolescent psychiatry or other pediatric subspecialists for assistance.

Figure.

Clinical decision flow chart.
PO, by mouth; IM, intramuscular; IV, intravenous; NGT, nasogastric tube; EtOH, ethanol; Utox, urine toxicology; PCP, phencyclidine; EPS, extrapyramidal symptoms; ASD, autism spectrum disorder; DD, developmental disability; BZD, benzodiazepines; ODT, orally dissolving tablet; PTSD, post-traumatic stress disorder; ADHD, attention deficit hyperactivity disorder; ODD, oppositional defiant disorder; CD, conduct disorder; pt, patient.
*For these etiologies, in absence of consensus, medication options are listed alphabetically; Do not give olanzapine and benzodiazepines within one hour of each other.

Agitation Due to Delirium. Delirium is a complex clinical syndrome in which underlying physical disease, pharmacologic factors or both cause acute onset of mental status change with fluctuating course, involving symptoms of inattention, altered level of awareness and other cognitive deficits.[24] Management of delirium requires identification and treatment of underlying etiologies. The initial approach should include reduction or discontinuation of medications that may be causing or exacerbating delirium. Pain should be treated while avoiding over-sedation and limiting exposure to opioid analgesia, which can worsen delirium. Medications may be needed to address underlying etiologies potentiating delirium, support sleep, and ameliorate physical symptoms such as pain or nausea. Medication for agitation can be necessary for safety, as well as avoiding medications that may worsen confusion or behavior in the setting of delirium, namely anticholinergics, benzodiazepines, and opioid analgesics.

Neuroleptics are the most commonly used pharmacologic intervention for delirium. Second-generation neuroleptics such as risperidone, olanzapine, and quetiapine have eclipsed haloperidol as the first-line agents.[25–27] Choice of neuroleptic should account for the patient's particular needs including route of administration, time to effect, potential side effects, illness factors, patient past experience with neuroleptics, and the specific symptoms of delirium being targeted. Clonidine may be used if there is reason to avoid neuroleptics. Melatonin may be helpful for sleep regulation if this is contributing to agitation.

Agitation Due to Substance Intoxication or Withdrawal. In cases of known or suspected substance intoxication or withdrawal, medication choice should be dictated by clinical presentation and the suspected substances. If urine toxicology is indicated, and the results are negative, newer synthetic drugs, such as synthetic cannabinoids and cathinones, should be suspected. Gas chromatography and mass spectrometry, where available, can also help to identify an ingestion. If the substance ingested is unknown, there is consensus that lorazepam should be used, and potentially combined with haloperidol if the patient is severely agitated or hallucinating.

Agitation in a Patient with Developmental Delay or Autism Spectrum Disorder. Youth with autism or developmental disabilities can be particularly vulnerable to ADEs from many of the medications commonly used to treat acute agitation, including benzodiazepines. Therefore, behavioral strategies are especially important in this population. Youth with autism or developmental disabilities often become agitated in the context of unrecognized physical or sensory discomfort, including headache, dental pain, gastrointestinal distress/constipation, and overstimulation. A detailed history from parents or guardians and close observation/examination can often elucidate potential triggers and inform treatment. A care plan with a list of specific triggers and calming strategies helps coordinate care across shifts in the ED setting. Asking parents or guardians about the child's prior medication responses, either positive or negative, can also inform choice of PRN medication. An extra dose of the child's regular standing medication may be preferable given risk of ADEs. IM administration should be avoided unless absolutely necessary for safety.

Agitation in the Context of Acute Psychiatric Illness. Agitation can occur in youth with a range of psychiatric illnesses, both acute and chronic. Missing home medications, at times due to waiting in the ED, is a frequent cause of agitation, so administering those home medications or administering an extra half or full dose can be effective. Youth with chronic psychiatric illness may alternatively become agitated for reasons that have nothing to do with their illness (e.g., a teen with a history of bipolar mania who is delirious, intoxicated, or in severe pain). Clinicians should also recall that mania and psychosis are rare in preadolescents; thus, a child presenting with agitation with disorganized thinking/behavior, hallucinations or delusions is more likely to be delirious, catatonic, or having difficulty communicating his or her experiences due to autism, intellectual disability, or psychological trauma.

Agitation of Unknown Etiology. While every effort should be made to identify the etiology of agitation, there will be patients for whom this is not possible, and the clinician should use his or her best judgment. For mild agitation, de-escalation strategies should be used while triggers for agitation are assessed. For moderate agitation, lorazepam, diphenhydramine or olanzapine can be used (though olanzapine and lorazepam should not be co-administered). For severe agitation, lorazepam can be combined with haloperidol, or chlorpromazine, or olanzapine can be used as single agents.

processing....